Caxton Associates LP acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,000 shares of the pharmaceutical company’s stock, valued at approximately $304,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of VRTX. Jennison Associates LLC increased its stake in shares of Vertex Pharmaceuticals by 253.8% during the second quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company’s stock worth $651,454,000 after acquiring an additional 3,626,368 shares during the period. Old Mutual Global Investors UK Ltd. increased its stake in shares of Vertex Pharmaceuticals by 1,384.7% during the second quarter. Old Mutual Global Investors UK Ltd. now owns 1,195,455 shares of the pharmaceutical company’s stock worth $154,058,000 after acquiring an additional 1,114,939 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Vertex Pharmaceuticals by 9,422.3% during the third quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock worth $135,829,000 after acquiring an additional 883,998 shares during the period. AJO LP acquired a new position in shares of Vertex Pharmaceuticals during the second quarter worth about $71,956,000. Finally, Vanguard Group Inc. increased its stake in shares of Vertex Pharmaceuticals by 3.1% during the second quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock worth $2,188,196,000 after acquiring an additional 504,982 shares during the period. Institutional investors own 93.33% of the company’s stock.
Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) opened at $142.53 on Friday. The firm has a market cap of $35,636.54, a price-to-earnings ratio of 234.85, a PEG ratio of 3.37 and a beta of 1.58. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $167.85.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.49. The business had revenue of $578.20 million during the quarter, compared to the consensus estimate of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The business’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.16 earnings per share. analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current fiscal year.
In other news, EVP Michael Parini sold 2,125 shares of the firm’s stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $152.93, for a total value of $324,976.25. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CMO Jeffrey Chodakewitz sold 1,718 shares of the firm’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $155.19, for a total transaction of $266,616.42. Following the completion of the transaction, the chief marketing officer now owns 116,142 shares in the company, valued at $18,024,076.98. The disclosure for this sale can be found here. Insiders have sold a total of 343,519 shares of company stock worth $49,488,660 over the last quarter. 1.80% of the stock is currently owned by insiders.
A number of analysts recently commented on the stock. Deutsche Bank assumed coverage on shares of Vertex Pharmaceuticals in a report on Tuesday. They set a “buy” rating and a $175.00 price objective on the stock. Cowen reissued a “buy” rating and set a $200.00 price objective on shares of Vertex Pharmaceuticals in a report on Monday. Royal Bank of Canada reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $195.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Finally, Robert W. Baird reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-four have issued a buy rating to the company’s stock. Vertex Pharmaceuticals has an average rating of “Buy” and a consensus target price of $173.22.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.